Recently, Shenzhen Ruispuri Biopharmaceutical Co., Ltd., a leading domestic inhalation high-end preparation research and development enterprise, completed a series B financing of more than 100 million yuan, led by Qianhai Fund of Funds and followed by Fuhui Venture Capital. It is understood that this round of funds will be mainly used to promote clinical research in the existing research pipeline, expand the construction of professional teams and promote the research and development of innovative drugs. The legal counseling service for this financing was provided by China Commercial Law Firm.
Previously, Respley announced in February 2021 that it had completed nearly 200 million yuan of Series B financing. At present, the investment and financing of the primary market of biomedicine is undervalued in stages, and Respley has completed 2 rounds of large financing in only 1 year, reflecting the strong comprehensive strength of the core team and the firm optimism of investors on the inhalation preparation track.
Founded in 2018 by Dr. Chen Yongqi, a senior pharmaceutical expert, Respuli is a comprehensive enterprise focusing on the research and development, production and sales of respiratory inhalation drug formulation technology and device. So far, Respril has built a quantitative inhalation aerosol (MDI), inhalation powder spray (DPI), nebulizer (Nebulizer), nasal spray (Nasal Spray) four major inhalation preparation research and development and production platform, the research product line covers a full range of respiratory system products, involving asthma (Asthma), chronic obstructive pulmonary disease (COPD), central nervous system diseases and other therapeutic areas with large clinical needs.
It is understood that Respli's first imitation product, RSG0101, will complete the BE filing within the year, and then enter the clinic, and will be listed as soon as 2023. In addition, Respril plans to advance two other high-end inhalation formulations into clinical trials in 2022.
Dr. Chen Yongqi, Chairman of Respley, expressed his gratitude to the new and old investors for their trust and support to Respley technology and team, as well as their profound grasp of the development trend of high-end inhalation preparations. Respley has always emphasized that "planning to be realistic, entrepreneurship to be realistic, people to be realistic", continue to welcome new and old shareholders, directors continue to strengthen supervision, escort For Respley, After nearly 4 years of hard work, Respley has formed a certain influence in the field of high-end inhalation preparations in China, the company's technology platform and R & D pipelines have also been iteratively upgraded, I believe that our Respley high-end inhalation preparation entrepreneurial undertakings will be able to go steady and far, bring excellent returns to investors, and create huge economic and social value for the society.
Dr. Duan Xufang, Executive Director of Qianhai Fund of Funds, said that we attach great importance to Dr. Chen Yongqi's extensive experience in the field of inhalation preparations, and the Respli he has formed is a rare top team in the field of powder mist inhalation preparations in China. Since its establishment, Respley has grown very rapidly, and the company's technology platform, R&D pipeline and governance structure have continued to improve, reflecting the team's strong execution and vitality. Qianhai Fund of Funds is pleased to participate in this round of financing with many professional medical investment institutions, which will also provide continuous support for the company's better development in the future.
Dr. Cheng Hao, a biomedical investment partner of Fuhui Venture Capital, pointed out that inhalation preparations are becoming a hot spot in the research and development of biopharmaceuticals at home and abroad, especially the powder mist inhalation preparation technology deeply cultivated by Dr. Chen Yongqi, which is releasing huge market potential. We are pleased to see that Respril, as a domestic biomedical enterprise, has rarely mastered the core technology of inhalation drug delivery owned by a few multinational pharmaceutical giants, and has built a rich research and development pipeline covering a number of top 100 billion dollars of blockbuster drug lists, and in just a few years, it has the ability to synchronize research and development in new biological antibody inhalation and multinational companies, and we hope to work with Resprey to jointly develop the broad market prospects for inhalation preparations.
In recent years, with the maturity of related technology platforms, high-end inhalation preparations have become a hot spot for enterprises and investment institutions in the biomedical field. Inhaled formulation is a drug dosage form that dissolves or disperses in a suitable medium, through a special drug delivery device, in the form of vapor or aerosol directly into the respiratory tract to the lungs to play a local or systemic therapeutic role, it can quickly and directly improve the efficacy, reduce the dose of administration, reduce the adverse reactions of the drug, is the preferred treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
The data shows that in recent years, the domestic urban and rural public hospitals, community centers and township health centers terminal inhalant drug market has expanded year by year, with an annual growth rate of 2 digits, breaking through the 20 billion yuan mark for the first time in 2018, reaching 23.68 billion yuan in 2019, an increase of 10.51% year-on-year. It is estimated that by 2023, the market size of terminal inhalation preparations in domestic public medical institutions will reach 34.67 billion yuan.
According to the different classification of the device, the inhalation preparation can be divided into different types such as inhalation powder aerosol (DPI), inhalation aerosol (MDI) and nebulized inhalation solution (NEB). Among them, dry powder inhalation preparations have risen rapidly because they can provide better effects for drugs for respiratory diseases. From the perspective of the product layout of the original pharmaceutical company, with the acceleration of the approval of compound preparations, the number of dry powder inhalation preparations listed in China has increased significantly, and the current compound preparations of top 2 in the mainland market size, Xinbico and Shulidei, are inhaled powder mist.
However, inhalation powder aerosol preparation is extremely difficult. In the preparation process, the solid micronized API alone or mixed with a suitable carrier, in the form of capsules, vesicles or multi-dose storage, using a special dry powder inhalation device, by the patient to absorb the atomization drug to the lungs of the preparation. How to determine the type of carrier, the details of the inhalation device grinding, etc., provide extremely high requirements for the preparation team. It is understood that Dr. Chen Yongqi has participated in the development of most of the world's heavy inhalation preparations and has rich experience in the research and development of inhalation drugs and the industry. After returning to China to start a business, Dr. Chen Yongqi is committed to the research and development and production of inhaled aerosol and inhalation powder spray administration for respiratory diseases, starting from the dry powder inhalation preparation platform, building a two-wheel drive research and development model of "high-end generic drugs + innovative drugs" for Respley, and promoting the development and research of domestic inhalation preparations into the fast lane.
About the Qianhai Fund
Qianhai Fund of Funds is a large-scale commercial fund of funds established in accordance with the spirit of "Supporting the Establishment of Qianhai Equity Investment Fund of Funds" in the Reply of the State Council on Supporting the Development and Opening Up of the Shenzhen Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone, and conforms to the general trend of the domestic equity investment fund of funds industry that is about to usher in the spring of development. Qianhai Fund of Funds gathers investor LPs with strength, influence and interactive resources in China, mainly including government, insurance and financial investment institutions, well-known enterprises and listed companies, etc., and at the same time gathers the fund of funds management team with the deepest understanding, the richest experience, the most extensive resources and the strongest management service capabilities in China. The partners of the management company are from the industry's top investment institutions, with an average investment management experience of more than 20 years, the scale of funds under management exceeds 100 billion, and the investment performance ranks among the best in the industry.
About Fuhui Venture Capital
Fuhui Venture Capital is a VC investment institution focusing on the transformation of scientific and technological achievements and the early investment of technology enterprises, specializing in investment in medical and health, advanced manufacturing and other fields, and the management team has rich experience in real industry and equity investment. The medical and health sector has invested in projects including Nuohui Health (06606. HK), Eagle Pupil Technology (02251. HK), Weizhen Biologics [Medical Devices], Jinbaihui Biologics [Medical Devices], Kaiskaidi [New Drug R&D], Zhiben Pharmaceutical [New Drug R&D], Nuland Bio [Exosomes], Huazi Bio [Long-acting Protein], Baiji Hongye [New Drug R&D], Youli Pharmaceutical [New Drug R&D], Luoqi Bio [Nano Antibody], Lingkang Times [Pharmaceutical CDMO], Ruishun Bio [Cell Therapy], Xinling Pharmaceutical [Transdermal Preparations], Hengsai Biologics [Cell Therapy] and many other high-quality enterprises.
*Cover image source: 123rf
![Gensy Bio officially opened the U.S. Innovation R&D Center[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)